Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO® (esketamine) CIII nasal spray, making ...
Imagine this — you’re caught up in a belly laugh with friends or engrossed in a gripping book when an urgent, uncontrollable need to dash to the bathroom hits out ...